Thomas E King Iii, MD | |
415 S 28th Ave, Hattiesburg, MS 39401-7246 | |
(601) 288-4329 | |
(601) 288-3191 |
Full Name | Thomas E King Iii |
---|---|
Gender | Male |
Speciality | Hospitalist |
Experience | 24 Years |
Location | 415 S 28th Ave, Hattiesburg, Mississippi |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1043324809 | NPI | - | NPPES |
009937023 | Medicaid | AL | |
02581770 | Medicaid | MS | |
1419893 | Medicaid | LA | |
640507572XZ | Other | MS | AMERICAN ADMIN GROUP |
P00184285 | Other | MS | RAILROAD MEDICARE |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208M00000X | Hospitalist | 17763 (Mississippi) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Forrest General Hospital | Hattiesburg, MS | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Hattiesburg Clinic, Pa | 5193706794 | 489 |
News Archive
Sigma-Aldrich Corporation announced today it has entered into a new gene editing partnership with the University of Michigan Medical School's Vector Core. Under the partnership, Sigma-Aldrich will provide the Vector Core with Sigma CRISPR technology, experimental design consultation, and dedicated gene editing bioinformaticians.
Biomedical engineers have grown miniature human blood vessels that exhibit many of the symptoms and drug reactions associated with Hutchinson-Gilford Progeria Syndrome - an extremely rare genetic disease that causes symptoms resembling accelerated aging in children.
Spherix Incorporated, an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis; and providers of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced that its Phase 2 diabetes clinical trial, designed to determine the minimum dose of D-tagatose capable of reducing HbA1c, found that the minimum dose capable of affecting HbA1c (7.5 g three-times daily, or TID) was within the range of doses tested
Results of a study, involving 98,454 patients demonstrated that at 30 days following their first heart attack, RA patients were approximately 20% less likely to be prescribed standard MI treatments, such as statins and betablockers, compared to healthy patients.
At least one in five people in countries for which data are available were infected with influenza during the first year of the 2009 H1N1 pandemic, according to a new study.
› Verified 2 days ago
Entity Name | Hattiesburg Clinic Pa |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1740213446 PECOS PAC ID: 5193706794 Enrollment ID: O20040528000685 |
News Archive
Sigma-Aldrich Corporation announced today it has entered into a new gene editing partnership with the University of Michigan Medical School's Vector Core. Under the partnership, Sigma-Aldrich will provide the Vector Core with Sigma CRISPR technology, experimental design consultation, and dedicated gene editing bioinformaticians.
Biomedical engineers have grown miniature human blood vessels that exhibit many of the symptoms and drug reactions associated with Hutchinson-Gilford Progeria Syndrome - an extremely rare genetic disease that causes symptoms resembling accelerated aging in children.
Spherix Incorporated, an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis; and providers of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced that its Phase 2 diabetes clinical trial, designed to determine the minimum dose of D-tagatose capable of reducing HbA1c, found that the minimum dose capable of affecting HbA1c (7.5 g three-times daily, or TID) was within the range of doses tested
Results of a study, involving 98,454 patients demonstrated that at 30 days following their first heart attack, RA patients were approximately 20% less likely to be prescribed standard MI treatments, such as statins and betablockers, compared to healthy patients.
At least one in five people in countries for which data are available were infected with influenza during the first year of the 2009 H1N1 pandemic, according to a new study.
› Verified 2 days ago
Entity Name | Forrest County General Hospital |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1295837631 PECOS PAC ID: 1052397767 Enrollment ID: O20040624001351 |
News Archive
Sigma-Aldrich Corporation announced today it has entered into a new gene editing partnership with the University of Michigan Medical School's Vector Core. Under the partnership, Sigma-Aldrich will provide the Vector Core with Sigma CRISPR technology, experimental design consultation, and dedicated gene editing bioinformaticians.
Biomedical engineers have grown miniature human blood vessels that exhibit many of the symptoms and drug reactions associated with Hutchinson-Gilford Progeria Syndrome - an extremely rare genetic disease that causes symptoms resembling accelerated aging in children.
Spherix Incorporated, an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis; and providers of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced that its Phase 2 diabetes clinical trial, designed to determine the minimum dose of D-tagatose capable of reducing HbA1c, found that the minimum dose capable of affecting HbA1c (7.5 g three-times daily, or TID) was within the range of doses tested
Results of a study, involving 98,454 patients demonstrated that at 30 days following their first heart attack, RA patients were approximately 20% less likely to be prescribed standard MI treatments, such as statins and betablockers, compared to healthy patients.
At least one in five people in countries for which data are available were infected with influenza during the first year of the 2009 H1N1 pandemic, according to a new study.
› Verified 2 days ago
Mailing Address | Practice Location Address |
---|---|
Thomas E King Iii, MD 415 S 28th Ave, Hattiesburg, MS 39401-7246 Ph: (601) 288-4329 | Thomas E King Iii, MD 415 S 28th Ave, Hattiesburg, MS 39401-7246 Ph: (601) 288-4329 |
News Archive
Sigma-Aldrich Corporation announced today it has entered into a new gene editing partnership with the University of Michigan Medical School's Vector Core. Under the partnership, Sigma-Aldrich will provide the Vector Core with Sigma CRISPR technology, experimental design consultation, and dedicated gene editing bioinformaticians.
Biomedical engineers have grown miniature human blood vessels that exhibit many of the symptoms and drug reactions associated with Hutchinson-Gilford Progeria Syndrome - an extremely rare genetic disease that causes symptoms resembling accelerated aging in children.
Spherix Incorporated, an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis; and providers of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced that its Phase 2 diabetes clinical trial, designed to determine the minimum dose of D-tagatose capable of reducing HbA1c, found that the minimum dose capable of affecting HbA1c (7.5 g three-times daily, or TID) was within the range of doses tested
Results of a study, involving 98,454 patients demonstrated that at 30 days following their first heart attack, RA patients were approximately 20% less likely to be prescribed standard MI treatments, such as statins and betablockers, compared to healthy patients.
At least one in five people in countries for which data are available were infected with influenza during the first year of the 2009 H1N1 pandemic, according to a new study.
› Verified 2 days ago
Kabeer Burman, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 415 S 28th Ave, Hattiesburg, MS 39401 Phone: 601-288-4329 Fax: 601-288-3191 | |
Mohammad Iffat Kabir Anindo, Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 415 S 28th Ave, Hattiesburg, MS 39401 Phone: 601-288-4329 Fax: 601-579-5240 | |
Manjunath Ramaiah, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 415 S 28th Ave, Hattiesburg, MS 39401 Phone: 601-288-4329 Fax: 601-288-3191 | |
George E Habeeb Jr., MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 415 S 28th Ave, Hattiesburg, MS 39401 Phone: 601-288-4329 Fax: 601-288-3191 | |
Ralph C Kahler, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 415 S 28th Ave, Hattiesburg, MS 39401 Phone: 601-296-2976 Fax: 601-579-5240 | |
Dr. Kelly W Ryder, D.O. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 415 S 28th Ave, Hattiesburg, MS 39401 Phone: 601-288-4329 |